- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-330
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.80 |
Change
-0.550(3.00%) |
Mkt cap ! $348.5M |
Open | High | Low | Value | Volume |
$18.36 | $18.47 | $17.55 | $108.5K | 6.064K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3 | $17.71 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.88 | 33 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 363 | 17.710 |
2 | 220 | 17.700 |
1 | 56 | 17.650 |
2 | 117 | 17.620 |
1 | 56 | 17.600 |
Price($) | Vol. | No. |
---|---|---|
17.910 | 32 | 2 |
17.980 | 11 | 1 |
17.990 | 9 | 1 |
18.000 | 1032 | 2 |
18.140 | 28 | 1 |
Last trade - 12.49pm 03/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online